Ask AI
HER2pos mBC

CE / CME

Advancing Precision Care and Shared Decision-making in 1L HER2+ mBC Management: Expert Insights, Patient Resources, and Adaptive Decision Support

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: June 16, 2025

Expiration: December 15, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Based on current FDA approvals and clinical practice guidelines, which of the following patients with HER2-positive breast cancer would be a candidate for frontline T-DXd?

2.

Which of the following findings was reported from the randomized, open-label phase III PATINA study evaluating the efficacy and safety of palbociclib combined with SoC anti-HER2 therapy plus ET vs anti-HER2 therapy plus ET alone after induction treatment in patients with HR-positive/HER2-positive mBC?

3.

Patient Case: 48-Yr-Old Woman With mBC Receiving T-DXd 



  • Sofia is a 48-yr-old woman with a history of HER2+ mBC

  • Her cancer recently progressed following 11 mo on adjuvant pertuzumab, trastuzumab, and taxane

  • She was started on T-DXd based on recent results from the  phase III DESTINY-Breast03 trial

  • She is an educated patient and asks you about the potential side effects with this new therapy and about “what to watch out for”

In addition to explaining potential for ILD/ pneumonitis with T-DXd, which of the following strategies would you implement to overcome clinical challenges regarding nausea/vomiting with this agent?